MiR-509 suppresses brain metastasis of breast cancer cells by modulating RhoC and TNF-α.

ABSTRACT: The median survival time of breast cancer patients with brain metastasis is less than 6 months, and even a small metastatic lesion often causes severe neurological disabilities. Because of the location of metastatic lesions, a surgical approach is limited and most chemotherapeutic drugs are ineffective owing to the blood brain barrier (BBB). Despite this clinical importance, the molecular basis of the brain metastasis is poorly understood. In this study, we have isolated RNA from samples obtained from primary breast tumors and also from brain metastatic lesions followed by microRNA profiling analysis. Our results revealed that the miR-509 is highly expressed in the primary tumors, whereas the expression of this microRNA is significantly decreased in the brain metastatic lesions. MicroRNA t

SUBMITTER: Xing F 

PROVIDER: S-EPMC4530094 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature